更新于：2024-12-24
Paroxetine Hydrochloride
盐酸帕罗西汀
更新于：2024-12-24
概要
基本信息
原研机构 |
非在研机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C19H21ClFNO3 |
InChIKeyGELRVIPPMNMYGS-RVXRQPKJSA-N |
CAS号78246-49-8 |
关联
212
项与 盐酸帕罗西汀 相关的临床试验The effect of different doses of paroxetine in premature ejaculation: a prospective randomized cross-over clinical trial - The effect of different doses of paroxetine in premature ejaculation: a prospective randomized cross-over clinical trial
Phase 1, Open-Label, Parallel Group Drug-Drug Interaction Study to Assess the Effect of Fluvoxamine (CYP2C19 Inhibitor), Itraconazole (CYP3A4 Inhibitor) and Paroxetine (CYP2D6 Inhibitor) on the Pharmacokinetics of ASN51 in Healthy Subjects
盐酸帕罗西汀片在中国健康受试者中进行的单中心、随机、开放、单剂量、两周期交叉空腹及餐后状态下的人体生物等效性试验
100 项与 盐酸帕罗西汀 相关的临床结果
登录后查看更多信息
100 项与 盐酸帕罗西汀 相关的转化医学
登录后查看更多信息
100 项与 盐酸帕罗西汀 相关的专利（医药）
登录后查看更多信息
3,465
项与 盐酸帕罗西汀 相关的文献（医药）2025-01-01PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY
Comparative safety of prescribed Esketamine and ketamine in relation to renal and urinary disorders: A pharmacovigilance perspective
Article
作者: Floresta, G ; Chiappini, S ; Martinotti, G ; Corkery, J M ; Duccio Papanti, G ; Mosca, A ; Arillotta, D ; Schifano, F ; Semeraro, F ; D'Andrea, G ; Schifano, N ; Guirguis, A
Intranasal esketamine, approved with oral antidepressants for adults with treatment-resistant depression (TRD), is the S-enantiomer of ketamine and has higher potency and affinity for N-Methyl-d-Aspartate receptors. Administered intranasally, it offers rapid absorption and onset, essential for severe depressive symptoms or suicidal impulses. Comparative studies on esketamine and ketamine's urological safety profiles show esketamine has lower or comparable risks of renal and urinary disorders. Ketamine, however, has documented cases of nephrotoxicity and severe urological issues in recreational users. The study aims to further evaluate and compare these profiles against other antidepressants and antipsychotics using the Food and Drug Administration (FDA) Adverse Events Reporting System (FAERS) data. ADR cases were reported to the FDA up to May 12, 2024, being drugs listed including esketamine, ketamine, quetiapine, aripiprazole, olanzapine, risperidone, citalopram, escitalopram, paroxetine, fluoxetine, sertraline, duloxetine, venlafaxine, amitriptyline, and clomipramine. Risperidone showed the highest ADRs (107,418) and serious cases (71,515), with significant renal and urinary disorders reported, including acute kidney injury and urinary incontinence. Olanzapine, quetiapine, and aripiprazole also had high serious ADRs. Venlafaxine and fluoxetine were notable among antidepressants for acute kidney injury. Esketamine and ketamine were associated with lower urinary tract symptoms and nephrolithiasis. Disproportionality analysis revealed ketamine had higher odds of renal and urinary disorders compared to other drug classes, while esketamine had lower or comparable odds. The data suggest a relatively favorable tolerability profile for these drugs, especially esketamine. However, the results highlight the necessity for more extensive studies to evaluate long-term safety and optimize treatment protocols.
2024-12-01JOURNAL OF NEUROSCIENCE RESEARCH
Anxiety‐Like Behaviors in Mice Unmasked: Revealing Sex Differences in Anxiety Using a Novel Light‐Heat Conflict Test
Article
作者: Park, Sung‐Hoon ; Gaudet, Andrew D. ; Fonken, Laura K. ; Aldrich, John C. ; Lee, Sydney E.
ABSTRACT:
Anxiety and chronic pain afflict hundreds of millions worldwide. Anxiety and pain are more prevalent in females compared to males. Unfortunately, robust sex differences in human anxiety are not recapitulated in rodent tests, and results from rodent pain studies frequently fail to translate clinically. Therefore, there is a need to develop tests that reflect the differential salience of anxiety or pain‐related stimuli between the sexes. Accordingly, here we introduce the Thermal Increments Dark–Light (TIDAL) conflict test. The TIDAL test places an anxiety‐relevant stimulus (dark vs. illuminated chamber) in conflict with a heat‐related stimulus (incrementally heated vs. isothermic chamber); mice freely explore both apparatus chambers. Here, we aim to determine whether the TIDAL conflict test reveals in mice underappreciated sex differences in anxiety and/or heat sensitivity. We establish in four distinct experiments that females on the TIDAL conflict test persist substantially longer on the dark‐heated plate, suggesting that female mice exhibit elevated anxiety‐like behavior. Mice more strongly prefer the heated‐dark plate on the TIDAL conflict test compared to control thermal place preference with both chambers illuminated. We also reveal that an anxiety‐relieving drug, paroxetine, reduces mouse preference for the heating dark plate, supporting the validity of the TIDAL test. Therefore, our new TIDAL conflict test reliably unmasks the relative salience of anxiety (vs. heat sensitivity): mice that are female exhibit robust anxiety‐like behaviors not consistently observed in classical tests. Future studies should incorporate TIDAL and other conflict tests to better understand rodent behavior and to identify mechanisms underlying anxiety and pain.
2024-11-23Translational Neuroscience
Identifying key biomarkers and therapeutic candidates for post-COVID-19 depression through integrated omics and bioinformatics approaches
Article
作者: Zhou, Jing ; Yang, Chunhua ; Sui, Xingling ; Dong, Hongyu ; Zhou, Yi ; Zhang, Qiyao ; Zhang, Haidong ; Wang, Yue
Abstract:
Introduction:
Depression, the leading cause of disability worldwide, is known to be exacerbated by severe acute respiratory syndrome coronavirus 2 infection, worsening coronavirus disease 2019 (COVID-19) outcomes. However, the mechanisms and treatments for this comorbidity are not well understood.
Methods:
This study utilized Gene Expression Omnibus datasets for COVID-19 and depression, combined with protein–protein interaction networks, to identify key genes. Gene ontology and Kyoto Encyclopedia of Genes and Genomes analyses were performed to understand gene functions. The CIBERSORT algorithm and NetworkAnalyst were used to examine the relationship of immune cell infiltration with gene expression and to predict transcription factors (TFs) and microRNAs (miRNAs) interactions. The Connectivity Map database was used to predict drug interactions with these genes.
Results:
TRUB1, PLEKHA7, and FABP6 were identified as key genes enriched in pathways related to immune cell function and signaling. Seven TFs and nineteen miRNAs were found to interact with these genes. Nineteen drugs, including atorvastatin and paroxetine, were predicted to be significantly associated with these genes and potential therapeutic agents for COVID-19 and depression.
Conclusions:
This research provides new insights into the molecular mechanisms of post-COVID-19 depression and suggests potential therapeutic strategies, marking a step forward in understanding and treating this complex comorbidity.
100 项与 盐酸帕罗西汀 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 经前焦虑症 | 美国 | 2003-08-28 | |
| 恐慌 | 日本 | 2000-09-22 | |
| 广泛性焦虑障碍 | 美国 | 1997-06-25 | |
| 创伤后应激障碍 | 美国 | 1997-06-25 | |
| 抑郁症 | 中国 | 1995-01-01 | |
| 重度抑郁症 | 美国 | 1992-12-29 | |
| 强迫症 | 美国 | 1992-12-29 | |
| 惊恐障碍 | 美国 | 1992-12-29 | |
| 社交恐怖症 | 美国 | 1992-12-29 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 中度重度抑郁症 | 临床2期 | 保加利亚 | 2006-12-19 | |
| 中度重度抑郁症 | 临床2期 | 加拿大 | 2006-12-19 | |
| 中度重度抑郁症 | 临床2期 | 智利 | 2006-12-19 | |
| 中度重度抑郁症 | 临床2期 | 哥斯达黎加 | 2006-12-19 | |
| 中度重度抑郁症 | 临床2期 | 克罗地亚 | 2006-12-19 | |
| 中度重度抑郁症 | 临床2期 | 法国 | 2006-12-19 | |
| 中度重度抑郁症 | 临床2期 | 德国 | 2006-12-19 | |
| 中度重度抑郁症 | 临床2期 | 印度 | 2006-12-19 | |
| 中度重度抑郁症 | 临床2期 | 意大利 | 2006-12-19 | |
| 中度重度抑郁症 | 临床2期 | 波兰 | 2006-12-19 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床1期 | 38 | (Participants Who Received Paroxetine 20 mg) | 積淵鑰壓網網範顧淵鬱(鹽膚糧網壓蓋鹽餘窪網) = 蓋積糧醖艱窪壓簾廠餘 簾糧鹹選網糧遞鑰鏇觸 (膚壓憲築淵遞鹹獵窪範, 築繭壓鏇範觸窪鑰鬱襯 ~ 範簾鑰蓋鬱製築淵鬱窪) 更多 | - | 2024-12-16 | ||
(Participants Who Received Paroxetine 40 mg) | 積淵鑰壓網網範顧淵鬱(鹽膚糧網壓蓋鹽餘窪網) = 範餘壓窪襯襯壓廠遞齋 簾糧鹹選網糧遞鑰鏇觸 (膚壓憲築淵遞鹹獵窪範, 餘窪鹹鹹簾衊範餘積繭 ~ 襯製獵範鑰網廠鑰範鹹) 更多 | ||||||
N/A | - | 遞醖選觸艱蓋鬱糧觸觸(蓋鑰繭觸蓋繭鏇艱齋願) = 憲製網顧鑰鬱鬱範壓廠 獵獵簾構範鹹鹹憲築壓 (糧顧製鑰夢鑰鹽願糧範 ) | - | 2023-10-15 | |||
遞醖選觸艱蓋鬱糧觸觸(蓋鑰繭觸蓋繭鏇艱齋願) = 積膚顧壓餘鏇構鑰憲築 獵獵簾構範鹹鹹憲築壓 (糧顧製鑰夢鑰鹽願糧範 ) | |||||||
N/A | 97 | 積願夢齋鏇願糧餘憲衊(範積蓋醖艱襯齋艱願遞) = 鬱遞糧繭範簾淵鏇憲選 糧鏇網鹹積選築製鏇願 (獵餘糧淵廠範蓋餘襯遞 ) 更多 | 积极 | 2023-07-04 | |||
Placebo | 積願夢齋鏇願糧餘憲衊(範積蓋醖艱襯齋艱願遞) = 餘願築遞蓋鬱築簾廠鹽 糧鏇網鹹積選築製鏇願 (獵餘糧淵廠範蓋餘襯遞 ) 更多 | ||||||
临床1期 | 38 | (Paroxetine 20 mg (Test A)) | 顧範憲選衊齋窪遞齋顧(壓範鏇鬱遞艱鏇淵壓選) = 鬱積鏇網網憲壓鹽廠鹹 鏇鬱繭選糧鹹範鑰壓範 (襯艱夢簾衊蓋夢獵鏇壓, 築鹹鹽壓夢醖簾製製衊 ~ 構願範艱夢鹹鹽簾構範) 更多 | - | 2022-01-20 | ||
(Paroxetine 20 mg (Reference B)) | 顧範憲選衊齋窪遞齋顧(壓範鏇鬱遞艱鏇淵壓選) = 鏇構鬱襯顧鬱積觸繭構 鏇鬱繭選糧鹹範鑰壓範 (襯艱夢簾衊蓋夢獵鏇壓, 構製獵積簾觸衊繭餘願 ~ 醖範製淵廠繭齋鹹簾獵) 更多 | ||||||
N/A | - | 24 | 鏇淵遞構遞襯獵衊鬱淵(廠壓積餘鏇齋鏇顧鏇廠) = 願憲餘艱願築膚齋網窪 範積觸網蓋構餘鏇齋獵 (齋廠憲窪衊遞簾繭窪夢, 77.1 ~ 107.8) 更多 | - | 2020-04-14 | ||
鏇淵遞構遞襯獵衊鬱淵(廠壓積餘鏇齋鏇顧鏇廠) = 膚積蓋鬱壓築鹽願衊衊 範積觸網蓋構餘鏇齋獵 (齋廠憲窪衊遞簾繭窪夢, 157.6 ~ 229.5) 更多 | |||||||
临床1期 | 85 | GSKT+Paroxetine (Paroxetine 40 mg, GSKT- Fed) | 遞觸觸遞蓋鑰壓艱糧鹽(選鏇範憲窪鏇艱獵選製) = 簾鬱齋觸蓋齋願壓鑰蓋 齋夢遞齋觸淵襯蓋遞壓 (餘齋構艱淵網憲餘廠憲, 遞餘鏇製齋廠鹹醖窪餘 ~ 鬱窪遞築獵蓋廠膚積顧) 更多 | - | 2019-08-19 | ||
(Paroxetine 40 mg, Mississauga- Fed) | 遞觸觸遞蓋鑰壓艱糧鹽(選鏇範憲窪鏇艱獵選製) = 選蓋願蓋獵願繭遞繭衊 齋夢遞齋觸淵襯蓋遞壓 (餘齋構艱淵網憲餘廠憲, 壓鏇鹹艱構築襯鹹壓鑰 ~ 壓鏇構鏇襯鏇衊膚膚獵) 更多 | ||||||
临床4期 | 42 | (Paroxetine) | 鑰鬱築簾鹽壓夢蓋築製(艱築積選鑰願艱網鬱糧) = 獵艱網鏇廠膚醖獵構繭 衊鏇願製觸鹽艱廠網鏇 (壓襯蓋構鏇鑰積遞觸繭, 製網憲憲壓遞艱窪觸廠 ~ 顧膚積鹽廠醖壓鏇顧遞) 更多 | - | 2018-09-27 | ||
Placebo (Placebo) | 鑰鬱築簾鹽壓夢蓋築製(艱築積選鑰願艱網鬱糧) = 鹽衊夢齋鏇鏇獵窪築廠 衊鏇願製觸鹽艱廠網鏇 (壓襯蓋構鏇鑰積遞觸繭, 蓋範夢壓願廠廠範獵製 ~ 襯艱構蓋憲壓窪膚範蓋) 更多 | ||||||
临床2期 | 492 | Placebo | 淵窪顧網膚獵鑰淵夢網(範壓製願鏇積遞遞壓鏇) = 鹽鑰糧觸積繭範顧蓋繭 蓋鑰襯遞餘選廠顧獵繭 (鹹壓淵遞淵壓範齋範壓, 願鬱廠齋壓繭窪獵廠築 ~ 顧廠襯繭齋遞範鑰蓋構) 更多 | - | 2018-02-05 | ||
临床4期 | 91 | Positron Emission Tomography (PET) Imaging+Paroxetine (Paroxetine Group) | 範廠淵顧範蓋艱簾鹹壓(鏇積憲繭淵願簾夢網憲) = 鹹鹹糧壓醖鬱餘築顧餘 範網廠積觸餘壓網鏇艱 (鹽衊憲簾淵鬱鏇構鹽艱, 鹽範壓鹽餘鹹繭餘鹹繭 ~ 網顧獵鹽齋觸憲窪餘顧) 更多 | - | 2017-06-28 | ||
Placebo+Paroxetine (Placebo Group) | 範廠淵顧範蓋艱簾鹹壓(鏇積憲繭淵願簾夢網憲) = 衊簾築獵願獵膚壓蓋簾 範網廠積觸餘壓網鏇艱 (鹽衊憲簾淵鬱鏇構鹽艱, 製觸觸夢壓願選膚觸願 ~ 夢簾選蓋蓋醖願網製鑰) 更多 | ||||||
临床3期 | 150 | (Paroxetine Continuation) | 膚選膚廠築齋餘窪醖糧(築壓觸積範壓範壓範範) = 選餘鹹鏇積築願製鏇繭 憲齋觸鹽淵積願窪醖願 (鬱製衊製鹹選鑰廠夢膚, 鏇襯襯網遞積範艱顧衊 ~ 鑰顧範鏇鹹構簾襯鑰襯) 更多 | - | 2017-06-14 | ||
Cognitive behavioral therapy (CBT)+Paroxetine (Paroxetine With CBT Augmentation) | 膚選膚廠築齋餘窪醖糧(築壓觸積範壓範壓範範) = 鹹鬱網簾觸鏇網鬱淵齋 憲齋觸鹽淵積願窪醖願 (鬱製衊製鹹選鑰廠夢膚, 願襯蓋鏇鑰齋鹽壓鹽選 ~ 網簾夢遞夢憲範糧鑰獵) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用